New HIV drug VH4524184 put to the test in healthy volunteers

NCT ID NCT07066722

Completed Knowledge-focused Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 1 study tested an experimental HIV drug called VH4524184 in 126 healthy adults aged 18 to 60. The goal was to see how the drug is absorbed by the body, how it behaves when taken with food, and whether it interacts with other common medicines like metformin or digoxin. The study did not test the drug's ability to treat HIV, only its safety and how it moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VH4524184
What this could lead to: If successful, this study could help determine the right dose and formulation of VH4524184 for future HIV treatment trials.
What could go wrong: This is an early-phase study in healthy volunteers, not people with HIV. It only measures drug levels and safety, not whether the drug works against HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Lenexa, Kansas, 66219, United States
GSK Investigational Site

Salt Lake City, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.